Satellos Bioscience (MSLE) Stock Price, News & Analysis

Company Overview

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.

Key Stats

• Today's Range: $5.99 to $6.38
• 50-Day Range: $5.59 to $8.70
• 52-Week Range: $4.53 to $13.39
• Volume: 38,775 shs
• Average Volume: 58,124 shs
• Market Capitalization: $132.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Satellos Bioscience Stock Analysis - MarketRank™

Satellos Bioscience scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Satellos Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Satellos Bioscience has a consensus price target of $18.00, representing about 198.8% upside from its current price of $6.02.

Amount of Analyst Coverage

Satellos Bioscience has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Satellos Bioscience are expected to decrease in the coming year, from ($1.69) to ($1.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Satellos Bioscience is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Satellos Bioscience has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.66% of the float of Satellos Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Satellos Bioscience has a short interest ratio ("days to cover") of 2.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Satellos Bioscience has recently decreased by 11.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Satellos Bioscience does not currently pay a dividend.

Dividend Growth

Satellos Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Satellos Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Satellos Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

37.90% of the stock of Satellos Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Satellos Bioscience has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/09/2026
• Oppenheimer CNS & Neuro-Muscular Summit: 6/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MSLE
• CIK: 1421642
• Web: N/A
• Phone: (905) 336-6128
• Fax: 604-602-9699
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Satellos Bioscience: $18.00
• High Price Target: $23.00
• Low Price Target: $11.00
• Potential Upside/Downside: +182.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.10%
• Return on Assets: -58.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.48
• Quick Ratio: 16.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.80 per share
• Price / Book: 3.54

Miscellaneous

• Outstanding Shares: 20,830,000
• Free Float: 12,936,000
• Market Cap: $132.90 million
• Optionable: N/A
• Beta: 1.55